Literature DB >> 13009494

The newer hematinics, their use and abuse.

W F LUTTGENS.   

Abstract

The newer hematinics are merely refinements of preexisting forms of treatment, but they have aided particularly in a better understanding of the deficiency states. The intrinsic factor of Castle has not been isolated from the gastric juice, and the interrelationships of this substance with the extrinsic factor (vitamin B(12)) and folic acid have not been defined at this time. Vitamin B(12) appears to be the active principle of refined liver extract and alone is probably adequate treatment for pernicious anemia. The other varieties of megaloblastic anemia may result from deficiency of vitamin B(12) or folic acid, although generally treatment with the latter brings about complete and lasting remission. The use of multihematinics and multivitamin preparations containing folic acid is to be condemned, particularly because of the possibility of their obscuring anemia and thwarting diagnosis of pernicious anemia until neurologic complications have taken place. Saccharated oxide of iron is a relatively safe preparation for intravenous administration, but the indications for its use are few. Because the body has no mechanism for iron excretion, only the amount of iron necessary to make up a deficiency should be given, although there is no definite evidence that hemochromatosis results from overdosage.

Entities:  

Keywords:  ANEMIA, IRON DEFICIENCY/therapy; ANEMIA, PERNICIOUS/therapy; FOLIC ACID/therapeutic use; IRON COMPOUNDS/therapeutic use; VITAMIN B12/therapeutic use

Mesh:

Substances:

Year:  1952        PMID: 13009494      PMCID: PMC1521536     

Source DB:  PubMed          Journal:  Calif Med        ISSN: 0008-1264


  37 in total

1.  The intravenous use of high molecular ferric carbohydrate compound in the treatment of hypochromic anemia.

Authors:  J E LUCAS; A B HAGEDORN
Journal:  Blood       Date:  1952-03       Impact factor: 22.113

2.  Effect of vitamin B12c in pernicious anemia and subacute combined degeneration of the cord.

Authors:  C C UNGLEY; H CAMPBELL
Journal:  Br Med J       Date:  1951-01-27

3.  Observations on the absorption, utilization, and excretion of vitamin B12.

Authors:  C L CONLEY; J R KREVANS; B F CHOW; C BARROWS; C A LANG
Journal:  J Lab Clin Med       Date:  1951-07

4.  Direct action of vitamin B12 upon human bone marrow; the effect of instillations of vitamin B12 and folic acid into the bone marrow as studied by nucleic acid staining techniques.

Authors:  D HORRIGAN; T JARROLD; R W VILTER
Journal:  J Clin Invest       Date:  1951-01       Impact factor: 14.808

5.  Anaemia of pregnancy treated with intravenous iron.

Authors:  J M SCOTT; A D T GOVAN
Journal:  Lancet       Date:  1951-02-17       Impact factor: 79.321

6.  Therapeutic effect of aureomycin in pernicious anemia.

Authors:  H LICHTMAN; V GINSBERG; J WATSON
Journal:  Proc Soc Exp Biol Med       Date:  1950-08

7.  Studies on the nature of the intrinsic factor of Castle.

Authors:  B E HALL
Journal:  Br Med J       Date:  1950-09-09

8.  The long-term evaluation of folic acid in the treatment of pernicious anemia.

Authors:  S O SCHWARTZ; S R KAPLAN; B E ARMSTRONG
Journal:  J Lab Clin Med       Date:  1950-06

9.  Oral treatment of pernicious anemia with subminimal doses of folic acid and vitamin B12.

Authors:  L M MEYER; A SAWITSKY; N D RITZ; M KRIM
Journal:  Am J Clin Pathol       Date:  1950-05       Impact factor: 2.493

10.  Vitamin B12 and related factors: a clinical and experimental review.

Authors:  R H GIRDWOOD
Journal:  Edinb Med J       Date:  1950-02
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.